ChemoCentryx ContactKeep Me PostedSite Map
Product Pipeline

Overview

CCR9 Program

CCR2 Program

CCR1 Program

C5aR Programs

ChemR23 Program

CXCR7 Program

Additional Programs

Partners

Additional Programs

ChemoCentryx is advancing several additional independent drug candidates through preclinical development, the most advanced of which target chemokine receptors involved in atopic dermatitis, inflammatory bowel disease, or IBD, including ulcerative colitis, liver inflammation, psoriasis, and RA.